Total Payments
$123,525
2024 Payments
$13,130
Companies
44
Transactions
533
Medicare Patients
18,585
Medicare Billing
$516,401
Payment Breakdown by Category
Research$110,737 (89.6%)
Food & Beverage$9,316 (7.5%)
Consulting$2,500 (2.0%)
Travel$927.19 (0.8%)
Education$44.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $110,737 | 16 | 89.6% |
| Food and Beverage | $9,316 | 503 | 7.5% |
| Consulting Fee | $2,500 | 1 | 2.0% |
| Travel and Lodging | $927.19 | 5 | 0.8% |
| Education | $44.99 | 8 | 0.0% |
Payments by Type
Research
$110,737
16 transactions
General
$12,788
517 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $114,259 | 23 | $0 (2024) |
| Novo Nordisk Inc | $1,493 | 88 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,253 | 69 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $766.42 | 36 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $652.12 | 35 | $0 (2024) |
| Amarin Pharma Inc. | $559.96 | 32 | $0 (2021) |
| Amgen Inc. | $537.70 | 26 | $0 (2024) |
| GlaxoSmithKline, LLC. | $523.88 | 32 | $0 (2024) |
| ABBVIE INC. | $490.87 | 22 | $0 (2024) |
| PFIZER INC. | $465.40 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,130 | 53 | Eli Lilly and Company ($12,000) |
| 2023 | $1,653 | 42 | Eli Lilly and Company ($882.96) |
| 2022 | $5,973 | 40 | Eli Lilly and Company ($5,289) |
| 2021 | $716.52 | 37 | Novo Nordisk Inc ($130.15) |
| 2020 | $24,761 | 45 | Eli Lilly and Company ($23,986) |
| 2019 | $16,143 | 65 | Eli Lilly and Company ($15,016) |
| 2018 | $56,738 | 98 | Eli Lilly and Company ($55,128) |
| 2017 | $4,411 | 153 | Eli Lilly and Company ($1,958) |
All Payment Transactions
533 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Respiratory | ||||||
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $86.94 | General |
| Category: Respiratory | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $26.22 | General |
| Category: Obesity | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/14/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: VACCINES | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.66 | General |
| 10/30/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $32.77 | General |
| Category: Biological | ||||||
| 10/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: Obesity | ||||||
| 10/16/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: Inflammation | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Respiratory | ||||||
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,000.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 09/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: Diabetes | ||||||
| 09/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: Obesity | ||||||
| 08/28/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Biological | ||||||
| 08/22/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.65 | General |
| Category: Inflammation | ||||||
| 08/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: NEUROSCIENCE | ||||||
| 08/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: RESPIRATORY | ||||||
| 08/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Obesity | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Respiratory | ||||||
| 07/31/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Diabetes | ||||||
| 06/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $37,063 | 3 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $35,946 | 4 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $31,842 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $3,949 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $608.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $447.00 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $297.96 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 3,981 | 6,061 | $488,513 | $95,986 |
| 2022 | 42 | 4,582 | 7,092 | $571,989 | $113,239 |
| 2021 | 40 | 4,918 | 7,781 | $590,648 | $123,274 |
| 2020 | 45 | 5,104 | 8,402 | $611,443 | $183,902 |
Total Patients
18,585
Total Services
29,336
Medicare Billing
$516,401
Procedure Codes
165
All Medicare Procedures & Services
165 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 306 | 853 | $191,925 | $28,844 | 15.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 244 | 244 | $83,204 | $8,227 | 9.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 134 | 192 | $29,376 | $7,525 | 25.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 310 | 673 | $6,057 | $5,653 | 93.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 69 | 70 | $12,810 | $5,284 | 41.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 274 | 309 | $21,939 | $5,086 | 23.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 295 | 386 | $22,002 | $5,051 | 23.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 255 | 495 | $20,295 | $4,703 | 23.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 300 | 499 | $16,467 | $3,797 | 23.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 233 | 239 | $10,755 | $2,474 | 23.0% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 194 | 278 | $10,008 | $2,305 | 23.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 65 | 66 | $4,950 | $1,996 | 40.3% |
| 82948 | Blood glucose (sugar) measurement using reagent strip | Office | 2023 | 196 | 398 | $5,572 | $1,966 | 35.3% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 80 | 80 | $4,960 | $1,514 | 30.5% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 87 | 99 | $6,336 | $1,463 | 23.1% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 11 | 11 | $1,892 | $1,439 | 76.0% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 79 | 105 | $4,095 | $928.20 | 22.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 23 | 24 | $3,000 | $696.24 | 23.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 67 | $5,025 | $610.40 | 12.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 24 | 26 | $2,548 | $594.55 | 23.3% |
| 84460 | Liver enzyme (sgpt), level | Office | 2023 | 99 | 113 | $2,599 | $586.47 | 22.6% |
| 84450 | Liver enzyme (sgot), level | Office | 2023 | 99 | 113 | $2,486 | $574.04 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,288 | $528.04 | 41.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 48 | 50 | $3,350 | $473.20 | 14.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 15 | 15 | $1,125 | $453.60 | 40.3% |
About Dr. John Nardandrea, MD
Dr. John Nardandrea, MD is a Family Medicine healthcare provider based in Ocala, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871572016.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Nardandrea, MD has received a total of $123,525 in payments from pharmaceutical and medical device companies, with $13,130 received in 2024. These payments were reported across 533 transactions from 44 companies. The most common payment nature is "" ($110,737).
As a Medicare-enrolled provider, Nardandrea has provided services to 18,585 Medicare beneficiaries, totaling 29,336 services with total Medicare billing of $516,401. Data is available for 4 years (2020–2023), covering 165 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Ocala, FL
- Active Since 01/16/2006
- Last Updated 01/19/2022
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1871572016
Products in Payments
- FARXIGA (Drug) $808.00
- JARDIANCE (Drug) $706.55
- Vascepa (Drug) $559.96
- TRELEGY ELLIPTA (Drug) $333.60
- Ozempic (Drug) $325.67
- Victoza (Drug) $315.44
- INVOKANA (Drug) $313.93
- VRAYLAR (Drug) $248.84
- XARELTO (Drug) $246.70
- Wegovy (Drug) $235.22
- Tresiba (Drug) $229.13
- SPRAVATO (Drug) $199.77
- Rybelsus (Drug) $198.96
- ClosureFast (Device) $176.08
- CONTRAVE (Drug) $168.91
- Repatha (Biological) $158.18
- Otezla (Drug) $146.50
- LYRICA (Drug) $145.43
- ANORO (Drug) $141.17
- Veozah (Drug) $135.97
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Ocala
Dr. David Oliver, Do, DO
Family Medicine — Payments: $249,809
Family Medicine $249,809
Dr. Sidney Clevinger, Md, MD
Family Medicine — Payments: $137,377
Family Medicine $137,377
Dr. Frank Fusco, M.d, M.D
Family Medicine — Payments: $23,767
Family Medicine $23,767
Robert Williams, Md, MD
Family Medicine — Payments: $18,761
Family Medicine $18,761
Dr. Grodonoff Nelson, D.o, D.O
Family Medicine — Payments: $14,434
Family Medicine $14,434
Kenneth Lee, Do, DO
Family Medicine — Payments: $11,430
Family Medicine $11,430